DCM Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

DCM Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-58,000	Closed	-$847K	–	303
2020 Q4	$847K	Buy	+58,000	New	+$769K	0.49%	67

Other funds holding GNMK

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM Advisors's GNMK Position: Q1 2021 in Review

DCM Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 58,000 shares — an estimated $847K sold.

DCM Advisors first reported a position in GNMK in Q4 2020 and held it in 1 quarter. The position peaked at $847K in Q4 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

DCM Advisors reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
DCM Advisors sold 58,000 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $847K.
DCM Advisors first reported a position in GenMark Diagnostics, Inc in Q4 2020 and held it in 1 quarter.
DCM Advisors's GenMark Diagnostics, Inc position peaked at $847K in Q4 2020.
164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on DCM Advisors's 13F filing for Q1 2021, filed 17 May 2021.